Phosphodiesterase-5 inhibitors in pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.

Jessica M Turner Francesca Maria Russo Jan A Deprest Ben-Willem J Mol Sailesh Kumar

Published in: BJOG : an international journal of obstetrics and gynaecology (2022)

PDE-5i use in pregnancy is associated with mild maternal side effects, lower operative birth for intrapartum fetal distress and a possible increase in persistent pulmonary hypertension of the newborn when used for the treatment of fetal growth restriction.

Keyphrases

pregnancy outcomes
pregnant women
pulmonary hypertension
birth weight
preterm birth
gestational age
pulmonary arterial hypertension
body mass index
combination therapy
smoking cessation